TP53BP1 and cancer: Inactivation not only of 53BP1, but also of its downstream effectors was shown to increase DNA damage tolerance of cancer-prone BRCA1−/− cells, most likely potentiating error prone HR pathways and increasing genome instability (Setiaputra and Durocher, 2019).